After PD-1 customization of patients, PD-1 receptors expressed in T cells can effectively bind to the ligands PD-L2 and PD-L1, thus inhibiting T-cell factor production and proliferation and at the same time suppressing tumor immunity. This evidence concerns the gene PDCD1LG2 and neoplasm.